The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -0.55 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2025, as Arcus Biosciences, Inc. reports it. History and quarterly detail are in the app.
- License and development services$221.0M
- Other Collaboration Revenue$26.0M
- Access rights$16.0M
- R&D services$10.0M
- License$7.0M
Leadership changes
From Arcus Biosciences, Inc.'s own filings, the day they're filed.
- Jennifer Jarrett · Chief Operating Officer · departureeff. 2026-03-30
- Merdad Parsey · Directors · departureeff. 2025-02-06
- Dietmar Berger M. · Chief Medical Officer · departureeff. 2025-02-06
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-05-05
- 10-Q · Quarterly report2026-05-05
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Arcus Biosciences, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Arcus Biosciences, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.